SAN DIEGO — Patients with idiopathic pulmonary fibrosis (IPF) had significant improvements in lung function and reversal of lung fibrosis measures after 12 weeks of therapy with an investigational inhibitor of the Hedgehog signaling pathway. Early efficacy data from a phase 2a safety trial suggest that the novel oral agent dubbed ENV-101 is associated with …
